Exploring tumor-normal cross-talk with TranNet: Role of the environment in tumor progression

There is a growing awareness that tumor-adjacent normal tissues used as control samples in cancer studies do not represent fully healthy tissues. Instead, they are intermediates between healthy tissues and tumors. The factors that contribute to the deviation of such control samples from healthy state include exposure to the tumor-promoting factors, tumor-related immune response, and other aspects of tumor microenvironment. Characterizing the relation between gene expression of tumor-adjacent control samples and tumors is fundamental for understanding roles of microenvironment in tumor initiation and progression, as well as for identification of diagnostic and prognostic biomarkers for cancers. To address the demand, we developed and validated TranNet, a computational approach that utilizes gene expression in matched control and tumor samples to study the relation between their gene expression profiles. TranNet infers a sparse weighted bipartite graph from gene expression profiles of matched control samples to tumors. The results allow us to identify predictors (potential regulators) of this transition. To our knowledge, TranNet is the first computational method to infer such dependencies. We applied TranNet to the data of several cancer types and their matched control samples from The Cancer Genome Atlas (TCGA). Many predictors identified by TranNet are genes associated with regulation by the tumor microenvironment as they are enriched in G-protein coupled receptor signaling, cell-to-cell communication, immune processes, and cell adhesion. Correspondingly, targets of inferred predictors are enriched in pathways related to tissue remodelling (including the epithelial-mesenchymal Transition (EMT)), immune response, and cell proliferation. This implies that the predictors are markers and potential stromal facilitators of tumor progression. Our results provide new insights into the relationships between tumor adjacent control sample, tumor and the tumor environment. Moreover, the set of predictors identified by TranNet will provide a valuable resource for future investigations.

[1]  Yong Cheng,et al.  Integrating Network Pharmacology and Transcriptomic Strategies to Explore the Pharmacological Mechanism of Hydroxysafflor Yellow A in Delaying Liver Aging , 2022, International journal of molecular sciences.

[2]  N. Heaton,et al.  Cellular glycan modification by B3GAT1 broadly restricts influenza virus infection , 2022, Nature Communications.

[3]  J. Fei,et al.  Characterization of the tumour microenvironment phenotypes in malignant tissues and pleural effusion from advanced osteoblastic osteosarcoma patients , 2022, Clinical and translational medicine.

[4]  T. Przytycka,et al.  Mutational Signatures as Sensors of Environmental Exposures: Analysis of Smoking-Induced Lung Tissue Remodeling , 2022, Biomolecules.

[5]  Chundi Gao,et al.  Development of a Clinical Prognostic Model for Metabolism-Related Genes in Squamous Lung Cancer and Correlation Analysis of Immune Microenvironment , 2022, BioMed research international.

[6]  Yu Zhou,et al.  KLF9 and EPYC acting as feature genes for osteoarthritis and their association with immune infiltration , 2022, Journal of Orthopaedic Surgery and Research.

[7]  Z. Shao,et al.  Stabilization of CCDC102B by Loss of RACK1 Through the CMA Pathway Promotes Breast Cancer Metastasis via Activation of the NF-κB Pathway , 2022, Frontiers in Oncology.

[8]  Yi-Chen Wu,et al.  LMX1B Activated Circular RNA GFRA1 Modulates the Tumorigenic Properties and Immune Escape of Prostate Cancer , 2022, Journal of immunology research.

[9]  B. Liu,et al.  Increased ATP2A1 Predicts Poor Prognosis in Patients With Colorectal Carcinoma , 2022, Frontiers in Genetics.

[10]  N. Jenkins,et al.  Ring Finger Protein 125 Is an Anti-Proliferative Tumor Suppressor in Hepatocellular Carcinoma , 2022, Cancers.

[11]  Bosheng Li,et al.  Role of lncSLCO1C1 in gastric cancer progression and resistance to oxaliplatin therapy , 2022, Clinical and translational medicine.

[12]  D. de Ruysscher,et al.  Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study , 2021, Cancers.

[13]  Rui Zhu,et al.  SLC13A4 Might Serve as a Prognostic Biomarker and be Correlated with Immune Infiltration into Head and Neck Squamous Cell Carcinoma , 2021, Pathology & Oncology Research.

[14]  Chan Yeong Kim,et al.  HumanNet v3: an improved database of human gene networks for disease research , 2021, Nucleic Acids Res..

[15]  Lele Song,et al.  Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels , 2021, Journal of hepatocellular carcinoma.

[16]  Xiufeng Wu,et al.  Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer , 2021, BMC Cancer.

[17]  X. Guan,et al.  Drivers and suppressors of triple-negative breast cancer , 2021, Proceedings of the National Academy of Sciences.

[18]  M. Fang,et al.  CLEC4s as Potential Therapeutic Targets in Hepatocellular Carcinoma Microenvironment , 2021, Frontiers in Cell and Developmental Biology.

[19]  W. Richer,et al.  Polyfunctional KLRG-1+CD57+ Senescent CD4+ T Cells Infiltrate Tumors and Are Expanded in Peripheral Blood From Breast Cancer Patients , 2021, Frontiers in Immunology.

[20]  A. Ignatov,et al.  The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer. , 2021, Cancer Biomarkers.

[21]  P. Bühlmann,et al.  Identifying cancer pathway dysregulations using differential causal effects , 2021, bioRxiv.

[22]  Yuhao Chen,et al.  The predictive prognostic values of CBFA2T3, STX3, DENR, EGLN1, FUT4, and PCDH7 in lung cancer , 2021, Annals of translational medicine.

[23]  Chang-Deng Hu,et al.  PRMT5: a putative oncogene and therapeutic target in prostate cancer , 2021, Cancer Gene Therapy.

[24]  Guixia Wang,et al.  Advances in Understanding the Roles of CD244 (SLAMF4) in Immune Regulation and Associated Diseases , 2021, Frontiers in Immunology.

[25]  M. Lulli,et al.  DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer , 2021, Cancer Research.

[26]  C. Kanduri,et al.  LY6K-AS lncRNA is a lung adenocarcinoma prognostic biomarker and regulator of mitotic progression , 2021, Oncogene.

[27]  Wenyan Kang,et al.  AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma , 2020, Frontiers in Oncology.

[28]  J. Borg,et al.  The Scribble family in cancer: twentieth anniversary , 2020, Oncogene.

[29]  W. Yuan,et al.  DEFB4A is a potential prognostic biomarker for colorectal cancer , 2020, Oncology letters.

[30]  Qiwei Zhang,et al.  Construction and Analysis of a circRNA-Mediated ceRNA Network in Lung Adenocarcinoma , 2020, OncoTargets and therapy.

[31]  J. M. Wessels,et al.  Brain-derived neurotrophic factor (BDNF) expression and function in the mammalian reproductive Tract. , 2020, Human reproduction update.

[32]  Yongxiu Yang,et al.  SPOCD1 accelerates ovarian cancer progression and inhibits cell apoptosis via the PI3K/AKT pathway , 2020, OncoTargets and therapy.

[33]  M. Lacey,et al.  Epigenetics of Skeletal Muscle-Associated Genes in the ASB, LRRC, TMEM, and OSBPL Gene Families , 2019, bioRxiv.

[34]  Shouping Xu,et al.  Upregulation of DLEU1 expression by epigenetic modification promotes tumorigenesis in human cancer , 2019, Journal of cellular physiology.

[35]  L. Zwiebel,et al.  Olfactory receptor gene abundance in invasive breast carcinoma , 2019, Scientific Reports.

[36]  A. Bruzzone,et al.  Prognostic significance of α‐ and β2‐adrenoceptor gene expression in breast cancer patients , 2019, British journal of clinical pharmacology.

[37]  Chen Li,et al.  Three Biomarkers Predict Gastric Cancer Patients' Susceptibility To Fluorouracil-based Chemotherapy , 2019, Journal of Cancer.

[38]  B. Stanger,et al.  Cellular Plasticity in Cancer. , 2019, Cancer discovery.

[39]  Chengliang Zhu,et al.  Hepatitis B virus X protein–induced SH2 domain–containing 5 (SH2D5) expression promotes hepatoma cell growth via an SH2D5–transketolase interaction , 2019, The Journal of Biological Chemistry.

[40]  P. Muñoz,et al.  Cancer cell plasticity: Impact on tumor progression and therapy response. , 2018, Seminars in cancer biology.

[41]  Na Ding,et al.  CENPI is overexpressed in colorectal cancer and regulates cell migration and invasion. , 2018, Gene.

[42]  Wei Chen,et al.  LncRNA FLVCR1‐AS1 acts as miR‐513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma , 2018, Journal of cellular biochemistry.

[43]  Ville Mustonen,et al.  The repertoire of mutational signatures in human cancer , 2018, Nature.

[44]  Benjamin E. Gross,et al.  Unifying cancer and normal RNA sequencing data from different sources , 2018, Scientific Data.

[45]  Min Min Chan,et al.  Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia , 2018, Leukemia.

[46]  Atul J Butte,et al.  Comprehensive analysis of normal adjacent to tumor transcriptomes , 2017, Nature Communications.

[47]  H. Sugimura,et al.  WDR62 overexpression is associated with a poor prognosis in patients with lung adenocarcinoma , 2017, Molecular carcinogenesis.

[48]  D. Scholtens,et al.  Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor‐negative breast cancer , 2017, International journal of cancer.

[49]  S. Sel,et al.  High neuronatin (NNAT) expression is associated with poor outcome in breast cancer , 2017, Virchows Archiv.

[50]  Takaaki Masuda,et al.  Phosphoserine Phosphatase Is a Novel Prognostic Biomarker on Chromosome 7 in Colorectal Cancer. , 2017, Anticancer research.

[51]  Wei Xiong,et al.  Role of tumor microenvironment in tumorigenesis , 2017, Journal of Cancer.

[52]  Rakesh Kumar,et al.  Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance. , 2016, Cancer research.

[53]  Jiaoti Huang,et al.  Functional screen identifies kinases driving prostate cancer visceral and bone metastasis , 2015, Proceedings of the National Academy of Sciences.

[54]  F. Nestle,et al.  TGF-β-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination , 2015, Current Biology.

[55]  E. Spindel,et al.  Role of Lynx1 and related Ly6 proteins as modulators of cholinergic signaling in normal and neoplastic bronchial epithelium. , 2015, International immunopharmacology.

[56]  Jay W. Shin,et al.  Batf2/Irf1 Induces Inflammatory Responses in Classically Activated Macrophages, Lipopolysaccharides, and Mycobacterial Infection , 2015, The Journal of Immunology.

[57]  Peter Crooks,et al.  Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells , 2015, Oncotarget.

[58]  Hyunju Lee,et al.  DEOD: uncovering dominant effects of cancer-driver genes based on a partial covariance selection method , 2015, Bioinform..

[59]  J. Grunewald,et al.  Gene expression analysis of membrane transporters and drug-metabolizing enzymes in the lung of healthy and COPD subjects , 2014, Pharmacology research & perspectives.

[60]  H. Brinkhaus,et al.  Mesenchymal precursor cells maintain the differentiation and proliferation potentials of breast epithelial cells , 2014, Breast Cancer Research.

[61]  Jian-Fu Chen,et al.  Microcephaly Disease Gene Wdr62 Regulates Mitotic Progression of Embryonic Neural Stem Cells and Brain Size , 2014, Nature Communications.

[62]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2013, Nature Medicine.

[63]  H. Toyoda,et al.  Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C. , 2013, Cytokine.

[64]  Sui Huang Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells , 2013, Cancer and Metastasis Reviews.

[65]  T. Jin,et al.  Association between Gαi2 and ELMO1/Dock180 connects chemokine signalling with Rac activation and metastasis , 2013, Nature Communications.

[66]  Sui Huang,et al.  Tumor progression: chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution. , 2012, Progress in biophysics and molecular biology.

[67]  Ming-Fei Lang,et al.  TAK1 in brain endothelial cells mediates fever and lethargy , 2011, The Journal of experimental medicine.

[68]  J. Rigo,et al.  The inhibitory neurotransmitter glycine modulates macrophage activity by activation of neutral amino acid transporters , 2010, Journal of neuroscience research.

[69]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[70]  R. Crystal,et al.  Smoking Is Associated with Shortened Airway Cilia , 2009, PloS one.

[71]  M. Wirth,et al.  Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease‐free interval and the number of metastases per patient , 2009, International journal of cancer.

[72]  Israel Steinfeld,et al.  BMC Bioinformatics BioMed Central , 2008 .

[73]  Yongdai Kim,et al.  A Gradient-Based Optimization Algorithm for LASSO , 2008 .

[74]  Chris Mungall,et al.  AmiGO: online access to ontology and annotation data , 2008, Bioinform..

[75]  Markus Ringnér,et al.  What is principal component analysis? , 2008, Nature Biotechnology.

[76]  H. El‐Serag,et al.  Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. , 2008, American journal of epidemiology.

[77]  M. Toribio,et al.  The DC-SIGN-related lectin LSECtin mediates antigen capture and pathogen binding by human myeloid cells. , 2007, Blood.

[78]  Yusuke Nakamura,et al.  Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer , 2007, Molecular Cancer Therapeutics.

[79]  A. Neugut,et al.  IGHMBP2 Thr671Ala polymorphism might be a modifier for the effects of cigarette smoking and PAH–DNA adducts to breast cancer risk , 2006, Breast Cancer Research and Treatment.

[80]  A. Puisieux,et al.  Metastasis: a question of life or death , 2006, Nature Reviews Cancer.

[81]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[82]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[83]  R. Sager Expression genetics in cancer: shifting the focus from DNA to RNA. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[84]  I. Johnstone,et al.  Ideal spatial adaptation by wavelet shrinkage , 1994 .

[85]  D. Grant Detoxification pathways in the liver , 1991, Journal of Inherited Metabolic Disease.

[86]  D. Bertsekas,et al.  TWO-METRIC PROJECTION METHODS FOR CONSTRAINED OPTIMIZATION* , 1984 .

[87]  J. Conejo-Garcia,et al.  The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds. , 2015, Advances in cancer research.

[88]  Andrew R. Green,et al.  Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast , 2008, Breast Cancer Research and Treatment.

[89]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..